Arrowhead regains NASDAQ compliance

August 12, 2009: With economic pressure on so many firms, and a not insignificant number folding in various industries, here’s some rare positive news: Arrowhead Research Corp., a firm with subsidiaries involved in carbon nanotubes and bioscience/medicine, has regained compliance with NASDAQ regulations requiring at least $2.5M in equity.

Key to the bounceback was a recent partnership for subsidiary Calando Pharmaceuticals, which applies self-assembling nanoparticles to therapeutic use of RNA interference, in addition to revised cost-controlled operations, noted Arrowhead president/CEO Christopher Anzalone, in a statement.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.